← Leaderboards
Soldano Ferrone
Roswell Park Cancer Institute Corp
$11,688,743
Attributed
$12,656,089
Total exposure
24
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2005–21$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$12,656,089 · 24
By mechanism
R01$8,309,418 · 6
R03$1,402,829 · 10
R21$961,015 · 3
P50$835,091 · 2
T32$593,426 · 1
P01$554,310 · 2
Top collaborators
- Cristina R. Ferrone5 shared
- Donald J Buchsbaum2 shared
- Gianpietro Dotti2 shared
- Kurt A Schalper2 shared
- Daniel A Vallera2 shared
- Dan Gabriel Duda1 shared
- Sareh Parangi1 shared
- Joseph Hasbrouck Schwab1 shared
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Robert A Fenstermaker$911,748
- Jeff C Hsu$56,109
Others in their field
Top investigators on “Tumor Antigens”
- William R Green · Dartmouth College$32,738,211
- John H Sampson · Duke University$30,849,602
- Catherine Ju-Ying Wu · Broad Institute, Inc.$30,485,072
- Elizabeth Marion Jaffee · Johns Hopkins University$26,862,085
- Ian M Thompson · University Of Texas Hlth Sci Ctr San Ant$24,066,354
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$20,250,477
Research focus
Tumor AntigensCellsMediatingBaseIn VitroResistanceMonoclonal AntibodiesTumorClinically SignificantDesignPeptidesNeoplastic CellMelanomaImmunotherapyCombinatorialPlayClinically RelevantStemTreatment EfficacyIn VivoDown-RegulationLesionCell LineNormal Tissue Morphology
Grant awards (65)
T cell plasticity, fusion proteins and CAR T cell-based immunotherapy of head and neck cancer$386,970
R01 · FY2021 · DE · contact PI
B7-H3 CAR T cell-based immunotherapy combined with Losartan to counteract desmoplasia for the treatment of Pancreatic Ductal Adenocarcinoma (PDAC)$167,163
R03 · FY2021 · CA · contact PI
Radiation and CSPG4-specifc CAR T cell based combinatorial therapy for the in vivo treatment of TNBC$83,660
R03 · FY2021 · CA · contact PI
T cell plasticity, fusion proteins and CAR T cell-based immunotherapy of head and neck cancer$386,970
R01 · FY2020 · DE · contact PI
Potential role of brachyury in HLA class I antigen processing machinery component downregulation in chordoma cells$89,856
R03 · FY2020 · CA · contact PI
ROLE OF THE HLA ANTIGEN PRESENTING MACHINERY (APM) IN RESISTANCE TO PD-1 AXIS BLOCKADE IN NON-SMALL CELL LUNG CANCER$83,795
R03 · FY2020 · CA
T cell plasticity, fusion proteins and CAR T cell-based immunotherapy of head and neck cancer$386,970
R01 · FY2019 · DE · contact PI
ROLE OF THE HLA ANTIGEN PRESENTING MACHINERY (APM) IN RESISTANCE TO PD-1 AXIS BLOCKADE IN NON-SMALL CELL LUNG CANCER$100,670
R03 · FY2019 · CA
Adaptive immunotherapy of anaplastic thyroid cancer$82,311
R03 · FY2019 · CA · contact PI
IL-15 TRiKES-based specific immunotherapy of pancreatic ductal adenocarcinoma$80,063
R03 · FY2019 · CA · contact PI
IL-15 TRiKES-based specific immunotherapy of TNBC; resistance mechanisms$80,063
R03 · FY2019 · CA · contact PI
Safety and anti-tumor activity of B7-H3 CAR T cells in TNBC$79,286
R03 · FY2019 · CA · contact PI
T cell plasticity, fusion proteins and CAR T cell-based immunotherapy of head and neck cancer$403,238
R01 · FY2018 · DE · contact PI
IL-15 TRiKES-based specific immunotherapy of pancreatic ductal adenocarcinoma$97,188
R03 · FY2018 · CA · contact PI
IL-15 TRiKES-based specific immunotherapy of TNBC; resistance mechanisms$97,125
R03 · FY2018 · CA · contact PI
Safety and anti-tumor activity of B7-H3 CAR T cells in TNBC$96,719
R03 · FY2018 · CA · contact PI
Safety and Efficacy of Vemurafenib and High-Dose InterferonAlpha-2b for Advanced Melanoma$267,874
P50 · FY2015 · CA · contact PI
Therapy of pancreatic cancer with 212Pb-labeled B7-H3 specific Ab and LDE225$201,799
R21 · FY2015 · CA
HSP based combinatorial immunotherapy in triple negative breast cancer$84,841
R03 · FY2015 · CA · contact PI
Safety and Efficacy of Vemurafenib and High-Dose InterferonAlpha-2b for Advanced Melanoma$279,210
P50 · FY2014 · CA · contact PI
Grp94 targeted therapy for pancreatic ductal adenocarcinoma$219,995
R21 · FY2014 · CA · contact PI
Therapy of pancreatic cancer with 212Pb-labeled B7-H3 specific Ab and LDE225$186,047
R21 · FY2014 · CA
HSP based combinatorial immunotherapy in triple negative breast cancer$84,841
R03 · FY2014 · CA · contact PI
Safety and Efficacy of Vemurafenib and High-Dose InterferonAlpha-2b for Advanced$288,007
P50 · FY2013 · CA · contact PI
Grp94 targeted therapy for pancreatic ductal adenocarcinoma$188,953
R21 · FY2013 · CA · contact PI
Combinatorial targeting of melanoma initiating cells$295,070
R01 · FY2012 · CA · contact PI
Combinatorial targeting of melanoma initiating cells$299,013
R01 · FY2011 · CA · contact PI
Combinatorial targeting of melanoma initiating cells$319,568
R01 · FY2010 · CA · contact PI
Antigen processing and HLA-peptide complexes in head and neck cancer$249,349
R01 · FY2010 · CA · contact PI
Dysregulated Expression of HLA Molecules, and Antigen Processing in Patients with$121,619
P01 · FY2010 · CA · contact PI
Antigen processing and HLA-peptide complexes in head and neck cancer$72,473
R01 · FY2010 · CA · contact PI
Antigen processing and HLA-peptide complexes in head and neck cancer$320,085
R01 · FY2009 · CA · contact PI
Combinatorial targeting of melanoma initiating cells$317,529
R01 · FY2009 · CA · contact PI
Dysregulated Expression of HLA Molecules, and Antigen Processing in Patients with$119,887
P01 · FY2009 · CA · contact PI
Antigen processing and HLA-peptide complexes in head and neck cancer$318,336
R01 · FY2008 · CA · contact PI
Combinatorial targeting of melanoma initiating cells$312,510
R01 · FY2008 · CA · contact PI
Rational Design of HMW-MAA Peptide Mimics$294,483
R01 · FY2008 · CA · contact PI
Dysregulated Expression of HLA Molecules, and Antigen Processing in Patients with$117,431
P01 · FY2008 · CA · contact PI
Antigen processing and HLA-peptide complexes in head and neck cancer$310,922
R01 · FY2007 · CA · contact PI
Rational Design of HMW-MAA Peptide Mimics$288,651
R01 · FY2007 · CA · contact PI
Dysregulated Expression of HLA Molecules, and Antigen Processing in Patients with$117,937
P01 · FY2007 · CA · contact PI
Rational Design of HMW-MAA Peptide Mimics$342,612
R01 · FY2006 · CA · contact PI
Antigen processing and HLA-peptide complexes in head and neck cancer$256,929
R01 · FY2006 · CA · contact PI
Dysregulated Expression of HLA Molecules, and Antigen Processing in Patients with$77,436
P01 · FY2006 · CA · contact PI
HLA Expression in Cancer$31,248
R03 · FY2006 · TW · contact PI
Rational Design of HMW-MAA Peptide Mimics$346,608
R01 · FY2005 · CA
MULTIDISCIPLINARY APPROACHES TUMOR IMMUNOLOGY$121,866
T32 · FY2005 · CA
HLA Expression in Cancer$32,000
R03 · FY2005 · TW
Rational Design of HMW-MAA Peptide Mimics$342,483
R01 · FY2004 · CA
HLA CLASS I PEPTIDE COMPLEX ADNORMALITIES IN MELANOMA$299,201
R01 · FY2004 · CA
MULTIDISCIPLINARY APPROACHES TUMOR IMMUNOLOGY$122,750
T32 · FY2004 · CA
HLA Expression in Cancer$32,000
R03 · FY2004 · TW
HLA CLASS I PEPTIDE COMPLEX ADNORMALITIES IN MELANOMA$22,451
R01 · FY2004 · CA
HLA CLASS I PEPTIDE COMPLEX ADNORMALITIES IN MELANOMA$318,327
R01 · FY2003 · CA
MULTIDISCIPLINARY APPROACHES TUMOR IMMUNOLOGY$117,150
T32 · FY2003 · CA
HLA CLASS I PEPTIDE COMPLEX ADNORMALITIES IN MELANOMA$340,099
R01 · FY2002 · CA
MULTIDISCIPLINARY APPROACHES TUMOR IMMUNOLOGY$117,850
T32 · FY2002 · CA
BREAKING UNRESPONSIVENESS TO A SELF-MAA$0
P01 · FY2002 · CA
HLA CLASS I PEPTIDE COMPLEX ADNORMALITIES IN MELANOMA$311,966
R01 · FY2001 · CA
BREAKING UNRESPONSIVENESS TO MAA WITH PETIDE MIMICS$262,650
R01 · FY2001 · CA
MULTIDISCIPLINARY APPROACHES TUMOR IMMUNOLOGY$113,810
T32 · FY2001 · CA
PEPTIDE MIMICS AND IMMUNOTHERAPY OF MELANOMA$96,829
R21 · FY2001 · CA
BREAKING UNRESPONSIVENESS TO MAA WITH PETIDE MIMICS$255,000
R01 · FY2000 · CA
HLA CLASS I ALLOSPECIFICITY ABNORMALITIES IN MEL$248,955
R01 · FY2000 · CA
PEPTIDE MIMICS AND IMMUNOTHERAPY OF MELANOMA$67,392
R21 · FY2000 · CA